Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG60ET)

Drug Name
GW-3965 Drug Info
Synonyms
GW3965; 405911-09-3; GW 3965; UNII-6JI5YOG7RC; GW-3965; 6JI5YOG7RC; CHEMBL59030; CHEBI:79995; (3-{3-[[2-CHLORO-3-(TRIFLUOROMETHYL)BENZYL](2,2-DIPHENYLETHYL)AMINO]PROPOXY}PHENYL)ACETIC ACID; 2-[3-[3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-[2,2-di(phenyl)ethyl]amino]propoxy]phenyl]acetic acid; [3-(3-{[2-Chloro-3-(Trifluoromethyl)benzyl](2,2-Diphenylethyl)amino}propoxy)phenyl]acetic Acid; GW-3965A; 3-(3-[[2-chloro-3-(trifluoromethyl)benzyl)(2,2-diphenylethyl)-amino]-propoxy}-phenyl acetic acid; GW 3965A
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Investigative [1]
Cross-matching ID
PubChem CID
447905
ChEBI ID
CHEBI:79995
CAS Number
CAS 405911-09-3
TTD Drug ID
DMG60ET

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Oxysterols receptor LXR-beta (NR1H2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VTB-38543 DMNY3J0 Atopic dermatitis EA80 Phase 2 [3]
2-Propanol, Isopropanol DML5O0H Discovery agent N.A. Investigative [4]
Desmosterol DMV8SUM Discovery agent N.A. Investigative [5]
L-783483 DM6OTGE Discovery agent N.A. Investigative [6]
WAY-214950 DM8ODI7 Discovery agent N.A. Investigative [2]
27-hydroxycholesterol DM2L6OZ Discovery agent N.A. Investigative [7]
22R-hydroxycholesterol DME8273 Discovery agent N.A. Investigative [8]
GSK-9772 DM4WS3R Discovery agent N.A. Investigative [9]
Riccardin C DM6MYGX Discovery agent N.A. Investigative [10]
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione DMH76SO Discovery agent N.A. Investigative [11]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Oxysterols receptor LXR-alpha (NR1H3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US9073931, E2 DMK9FJG N. A. N. A. Patented [12]
BDBM50177019 DMEL28G N. A. N. A. Patented [13]
US9006244, E2b DMP0TBO N. A. N. A. Patented [14]
US9073931, E1 DM2Z43I N. A. N. A. Patented [12]
US9006244, E1 DMBF1C0 N. A. N. A. Patented [14]
BDBM50177012 DM52IQF N. A. N. A. Patented [13]
US9006244, E2a DMPDF9B N. A. N. A. Patented [14]
67S DMJL1MB N. A. N. A. Patented [13]
US9073931, E3 DMCYM8P N. A. N. A. Patented [12]
Desmosterol DMV8SUM Discovery agent N.A. Investigative [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oxysterols receptor LXR-alpha (NR1H3) TTECBXN NR1H3_HUMAN Inhibitor [2]
Oxysterols receptor LXR-beta (NR1H2) TTXA6PH NR1H2_HUMAN Inhibitor [2]

References

1 Liver X receptor in the hippocampus: A potential novel target for the treatment of major depressive disorder Neuropharmacology. 2018 Jun;135:514-528.
2 Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5 Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
6 A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
7 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
8 An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
9 Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
10 Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
11 Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
12 Liver X receptor modulators. US9073931.
13 Piperazine derivatives as liver X receptor modulators. US10144715.
14 Liver X receptor modulators. US9006244.